TIDMRENE

RNS Number : 5573K

ReNeuron Group plc

02 September 2021

ReNeuron Group plc

("ReNeuron" or the "Company")

Block Listing Review, Block Listing Application

and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

 
 Name:                               ReNeuron Group plc 
 Name of Scheme:                     ReNeuron Share Option Schemes 
                                    -------------------------------------- 
 Period of Return:                   From 1 March 2021 to 31 August 2021 
                                    -------------------------------------- 
 Balance of unallotted securities    663,687 Ordinary Shares (of 1p each) 
  under scheme(s) from previous 
  return: 
                                    -------------------------------------- 
 Plus : The amount by which          N/A 
  the block scheme(s) has been 
  increased since the date 
  of the last Review (if any 
  increase has been applied 
  for): 
                                    -------------------------------------- 
 Less : Number of securities 
  issued/allotted under scheme(s) 
  during period                      80,697 
                                    -------------------------------------- 
 Equals : Balance under scheme(s)    582,990 Ordinary Shares 
  not yet issued/allotted at 
  end of period: 
                                    -------------------------------------- 
 Number and class of securities      20,000 ordinary shares on 13 May 2010 
  originally admitted and the 
  date of admission: 
                                    -------------------------------------- 
 

Block Listing Application

Given the number of options under the existing Share Option Scheme, the Company announces that it has made an application to the London Stock Exchange for a block listing of 3,000,000 additional new ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") to be admitted to AIM.

The Ordinary Shares will be issued from time to time pursuant to the Company's existing plans including outstanding options already issued but not yet exercised to the employees of the Company.

When issued, the Ordinary Shares under this block listing will rank pari passu with the Company's existing issued Ordinary Shares. It is expected that admission will be effective on 3 September 2021.

Total Voting Rights

At 31 August 2021, the Company had 56,936,402 Ordinary Shares in issue, each carrying one voting right.

As the Company holds no ordinary shares in treasury, the figure of 56,936,402 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

ENDS

Contacts:

 
 ReNeuron                                                        www.reneuron.com/investors 
 Olav Hellebø, Chief Executive                                         Via Walbrook PR 
  Officer 
 
 Stifel Nicolaus Europe Limited (NOMAD 
  and Joint Broker) 
  Ben Maddison, Stewart Wallace                                         +44 (0)20 7710 7600 
 
 Allenby Capital Limited (Joint Broker)                                 +44 (0)20 3328 5656 
 James Reeve/George Payne (Corporate 
  Finance) 
 Stefano Aquilino (Sales & Corporate 
  Broking) 
 
 Walbrook PR (Media & Investor Relations)    +44 (0)20 7933 8780 or reneuron@walbrookpr.com 
                                                          +44 (0)7980 541 893 / +44 (0)7407 
 Paul McManus, Alice Woodings                                                       804 654 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREAENAESAFEFA

(END) Dow Jones Newswires

September 02, 2021 07:00 ET (11:00 GMT)

Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Reneuron.
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Reneuron.